Unlike most solid tumours, the incidence and mortality of hepatocellular carcinoma (HCC) have increased in the United States and Europe in the past decade. Most patients are diagnosed at advanced stages, so there is an urgent need for new systemic therapies. Studies in patients with lung, breast or colorectal cancers have indicated that the heterogeneity of cancer cells within a tumour affect its response to therapeutics designed to target-specific molecules. When tumour progression requires alterations in specific signalling pathways, drugs that selectively block them might slow tumour growth. Identification of molecules that mediate tumour progression, and trials that monitor them as biomarkers, might lead to personalised therapy; reagents that interfere with signalling pathways required for HCC progression might be used to treat selected populations, and thereby maximise the efficacy and cost benefit. However, no specific alterations are yet known to be implicated in HCC progression, so it is important to improve our understanding of its molecular pathogenesis.

Mitogen-activated protein kinases (MAPKs), serine/threonine-specific protein kinases, respond to extracellular stimuli and have a pivotal role in various cellular processes, such as gene expression, mitosis, differentiation, proliferation and cell survival/apoptosis ([@bib3]; [@bib5]). Mitogen-activated protein kinase comprises the extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK) and p38MAPK. Accumulating evidence suggests that activation or inactivation of MAPK regulates inflammatory responses and provides a growth advantage to hepatocytes during malignant transformation and liver tumourigenesis ([@bib16], [@bib14]; [@bib8]; [@bib19]). Abnormal activation of ERK is often observed in human HCC. It has been shown that systemic administration of sorafenib, a tyrosine kinase inhibitor targeting the Raf/ERK pathway, extended the survival of patients with advanced-stage HCC significantly in several clinical trials ([@bib1]; [@bib11]). Mouse cancer models have shown that the JNK pathway is implicated in regulating liver carcinogenesis. c-Jun N-terminal kinase activation contributes to hepatocyte proliferation and HCC development by regulating cyclin D and vascular endothelial growth factor (VEGF), a potent proangiogenic substance responsible for tumour neovascularisation ([@bib17]; [@bib16]; [@bib15]). c-Jun, a downstream target of JNK, promotes chemically induced liver cancer development through suppression of the p53 pathway ([@bib6]). Proliferation of HCC cells requires JNK-dependent downregulation of p21 ([@bib9]). However, the extent of the involvement of JNK in the development of human liver cancers is unknown. Recently, we have reported that activation of JNK in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma, suggesting the importance of JNK in human HCC ([@bib7]).

A novel theory in the field of tumour biology postulates that the capacity to maintain tumour formation and growth is found in a small population of cells, called tumour-initiating cells or cancer stem cells. The stem cell-like characteristics of these cells are believed to render these cells resistant to conventional therapies and allow them to drive tumourigenesis. CD133, a transmembrance glycoprotein, is a valuable marker of cancer stem cell and is expressed in 1--5% of human HCC, while absent in normal liver cells ([@bib12]). In addition to its role as a marker, CD133 has been reported to play a functional part in regulating tumourigenesis of liver cancer stem cells via regulating IL-8, CXCL1 and ERK signalling ([@bib18]).

Patients and methods
====================

Patients
--------

From May 2009 to June 2010, 39 patients with refractory HCC, which could not be controlled by standard therapeutic modalities, received sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals, LeverKusen, Germany) at Kinki University Hospital. All pathological specimens of HCC were taken by needle biopsy before sorafenib treatment.

The study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were approved by the institutional review boards. Written informed consent was obtained from all patients for subsequent use of their collected tissues.

Eligibility criteria, treatment regimen and assessment of response to sorafenib
-------------------------------------------------------------------------------

The eligibility criteria for sorafenib therapy were (1) advanced HCC, which was uncontrollable with standard treatments, or HCC with distant metastasis; (2) age \<81 years; (3) an Eastern Cooperative Group performance status of 0 or 1; (4) Child-Pugh grade A; (5) encephalopathy degree 0; (6) leukocyte count \>3000 cells mm^−3^, haemoglobin level \>10 g dl^−1^, platelet count \>80 000 cells mm^−3^; and (7) serum creatinine \<1.5 mg dl^−1^, serum aspartate aminotransferase \<200 IU l^−1^, serum alanine aminotransferase \<200 IU l^−1^ and serum total bilirubin \<3.0 mg dl^−1^. These criteria were based on the susceptibility to adverse side effects. The diagnosis of HCC was made based on haematoxylin--eosin staining of histopathological specimens in all patients.

Sorafenib was given orally at a daily dose of 800 mg, divided into two equal doses. Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) were permitted for drug-related adverse effects (National Cancer Institute-Common Terminology Criteria (NCI-CTC, version 3)). Treatment was continued until the occurrence of radiologic progression, as defined by the Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.1).

Assessed by contrast enhanced computed tomography or magnetic resonance imaging every 4 weeks, therapeutic response to sorafenib was defined according to the criteria of RECIST (Version 1.1). A partial response (PR) was defined as at least 30% decrease in the sum of the longest diameter of target lesions with the baseline sum of the longest diameter of target lesions as the reference. Progressive disease (PD) was defined as at least 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) was defined as meeting neither PR nor PD criteria. When the response achieved for intrahepatic HCC differed from that for extrahepatic HCC, the worse response was determined as the achieved response. Assessment of response was introduced best overall response of RECIST.

Immunohistochemistry
--------------------

Immunohistochemical analysis was performed on paraffin sections of human HCC and mouse tumours. Immunohistochemical staining was carried out with antibodies raised against phospho-c-Jun (Ser63; 1 : 100), phospho-JNK (1 : 100) and CD133 (1 : 100) from Cell Signaling Technology (Danvers, MA, USA) and visualised using Dako LSAB System-HRP (Dako, Carpinteria, CA, USA). Five fields of images per sample were taken and total and stain-positive nuclei were counted by Image J software (NIH, Bethesda, MD, USA).

Western blot analysis
---------------------

To prepare tissue lysate, HCC tissue was homogenised with CelLytic-MT Mammalian Tissue Lysis/Extraction reagent (Sigma-Aldrich, St Louis, MO, USA) with protease inhibitor, Complete (Roche Diagnostics, Mannheim, Germany), and phosphatase inhibitor (Toyobo, Osaka, Japan) and centrifuged. Equal protein amounts of tissue lysates were electrophoresed through a reducing SDS polyacrylamide gel and electroblotted onto a PVDF membrane. The membrane was blocked and incubated with primary antibodies for CD133, phospho-c-Jun, c-Jun, phospho-ERK1/2, ERK1/2 from Cell Signaling Technology (Beverly, MA, USA) and *β*-actin (Sigma-Aldrich). The levels of each protein were detected with horseradish peroxide-linked secondary antibodies and the ECL plus System (GE Healthcare, Piscataway, NJ, USA). To evaluate the signal intensity, obtained western blot image data were quantified using Image J software (NIH).

Inoculation of sorted CD133^+^HCC cells into nude mice
------------------------------------------------------

Human liver cancer cell line HepG2 and HuH7 obtained from the Riken Cell Bank (Tsukuba, Japan) were cultured in DMEM with 100 U ml^−1^ penicillin, 100 *μ*g ml^−1^ streptomycin and 10% (FBS) at 37 °C under 5% CO~2~/95% air. For isolating CD133-positive and -negative cells, cells were collected by trypsin treatment, washed twice with 1% BSA/PBS and labelled with anti-CD133-allophycocyanin antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) for 20 min on ice, in the dark. Then, cells were washed once in ice-cold 1% BSA/PBS, and sorted on a FACS Vantage SE (BD, San Diego, CA, USA). CD133-positive and -negative cells were collected separately, washed with PBS and cultured under normal condition for 5 days. Cells were collected by trypsin treatment and suspended in mixture of DMEM and Matrigel (BD) (1 : 1), and injected. CD133^+^ cells were subcutaneously inoculated into 6-week-old female BALB/c nude mice. From 1 week after subcutaneous inoculation, TAT control peptide and D-JNKi were administered at 25 nmol per mouse once a week and the mice were autopsied 4 weeks later. D-JNKi is an efficient inhibitor of the action of all three JNK isoforms and is made by linking the 20 amino-acid terminal JNK-inhibitory sequence (i.e., the JNK-binding domain of JIP-1/IB1) to a 10-amino acid HIV-TAT transporter sequence.

All animal procedures were performed according to approved protocols and in accordance with the recommendations for the proper care and use of laboratory animals. The Medical Ethics Committee of Kinki University School of Medicine approved the present study.

Statistical analysis
--------------------

Relationships between the parameters of the patients treated with sorafenib were investigated using Student\'s *t*-test, the Mann--Whitney *U*-test and Fisher\'s exact test. Cumulative survival and time-to-progression (TTP) curves were constructed using the Kaplan--Meier method and compared using the log-rank test. The relationship between numeric data (e.g., number on PCNA-positive tumour cells) was determined using Student\'s *t*-test. All analyses were performed using the SPSS software (version 11.5; SPSS Inc., Chicago, IL, USA).

Results
=======

Association between JNK activation and poor therapeutic response to sorafenib
-----------------------------------------------------------------------------

Among 39 patients treated, a complete response and PR was achieved in 0 (0%) and 5 (12.8%), respectively. The overall response rate was 12.8%. Stable disease was noted in 13 patients (33%), and the disease control rate (complete response+PR+SD) was 46.2%. Progressive disease was noted in 17 patients (43.6%). Four patients were excluded from the assessment of response because they died of rupture of HCC or of oesophageal varices after the start of treatment and computed tomography could not be performed. No significant difference was observed in any of nine parameters such as age, sex, the cause of disease, tumour grade or previous therapy, between the responder group and the non-responder group ([Table 1](#tbl1){ref-type="table"}). We evaluated the change in tumour blood flow by using CT scan to confirm how sorafenib worked. In 13 out of 18 responders (72%), arterial blood supply was decreased while in 8 out of 17 non-responders (47%) the arterial blood flow was decreased.

We investigated the association between the therapeutic response to sorafenib and JNK activation using HCC specimens collected before treatment. As shown in [Figure 1](#fig1){ref-type="fig"}, phospho-JNK/c-Jun expression in HCC cells was significantly higher in the non-responder group than in the responder group.

Association between JNK activation and poor prognosis in patients treated with sorafenib
----------------------------------------------------------------------------------------

The median TTP was 2.0 months (95% confidence interval: 0--7.9 months). The cumulative progression-free survival rates at 3, 6 and 12 months were 49%, 44% and 29%, respectively. All enrolled patients were also included in a survival assessment. Twenty-five patients were still alive at the end of the observation period (median: 6.0 months, range: 1.3--12.1 months), while 14 patients had died. The causes of death were tumour progression (*n*=10) and rupture of HCC or oesophageal varices (*n*=4). The median survival time was 12.1 months (95% confidence interval: 7.9--16.4 months). The cumulative survival rate at 3, 6 and 12 months were 81%, 75% and 56%, respectively.

We examined the impact of JNK activation in HCC cells on the prognosis of patients treated with sorafenib. Hepatocellular carcinoma specimens collected by needle biopsy before sorafenib treatment were stained with anti-phospho-c-Jun antibody and the data were quantified. Patients were divided into high and low p-c-Jun expression groups by setting the median level as the cutoff between the two groups. As shown in [Figure 2A](#fig2){ref-type="fig"}, a log-rank test using the Kaplan--Meier method showed significant TTP prolongation in the low p-c-Jun expression group, compared with the high expression group (*P*=0.0028). We also found significant prolongation of overall survival (OS) in the low p-c-Jun expression group compared with the high expression group (*P*=0.0008; [Figure 2B](#fig2){ref-type="fig"}). The duration of sorafenib treatment was 151±116 days in the low p-c-Jun group and 80±97 days in the high p-c-Jun group.

Association between JNK activation and CD133 expression in human HCCs
---------------------------------------------------------------------

In patients treated with sorafenib, expressions of CD133, phospho-c-Jun and phospho-ERK were examined. Hepatocellular carcinomas positive for CD133 was also positive for phospho-c-Jun and phospho-JNK ([Figure 3A](#fig3){ref-type="fig"}). There was a significant positive correlation between CD133 and phospho-c-Jun expressions (*r*=0.854 and *P*=0.007). In contrast, there was no correlation between CD133 and phospho-ERK expressions (*r*=0.254 and *P*=0.544) ([Figure 3B](#fig3){ref-type="fig"}).

In patients treated with sorafenib, correlation between CD133 expression and efficiency of sorafenib treatment was examined. Among 17 objective non-responders (PD), 8 cases exhibited CD133-positive cells. In contrast, among 18 objective responders (PR or SD), only 3 cases exhibited CD133-positive cells. There was a significant correlation between CD133 expression and response to sorafenib (*P*=0.027) ([Figure 4B](#fig4){ref-type="fig"}). According to the status of HCC at the initiation of sorafenib treatment, patients were classified as B (intermediate) or C (advanced) using Barcelona Clinic Liver Cancer (BCLC) staging system. There was no significant difference in JNK activity or CD133 positivity between BCLC stage B and stage C HCCs (data not shown).

We utilised FACS sorting to isolate CD133-positive and CD133-negative cells from HepG2 cells. CD133^+^ cells and CD133^−^ cells were inoculated subcutaneously at 8 × 10^4^ cells per body into nude mice. From 1 week after subcutaneous inoculation, TAT control peptide and D-JNKi were administered at 25 nmol per mouse once a week and the mice were autopsied 4 weeks later. After autopsy, the volume of tumours was measured. CD133^+^ cells could efficiently initiate tumours in mude mice compared with CD133^−^ cells ([Figure 5A](#fig5){ref-type="fig"}). CD133^+^ HepG2 cells produced large tumours in 100% of mice whereas CD133^−^ cell fractions produced only small tumours in 50% of mice. On the other hand, mice treated with D-JNKi showed a marked reduction in tumour-initiating capacity of CD133^+^ cells to the same level as in CD133^−^ cells ([Figure 5B](#fig5){ref-type="fig"}). Similar results were obtained using another HCC cell line, a HuH7 cell ([Figure 5C and D](#fig5){ref-type="fig"}). Indeed, D-JNKi suppressed the expression of p-c-Jun and p-JNK in HCC ([Figure 5E and F](#fig5){ref-type="fig"}) and p-c-Jun in HepG2 cells ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Discussion
==========

The therapeutic options for advanced-stage HCC are limited because HCC responds poorly to systemic treatments such as conventional chemotherapy and radiotherapy. Cancer stem cells may be more resistant to chemotherapeutic agents than differentiated tumour cells possibly owing to an increased expression of adenosine triphosphate-binding cassette transporters and anti-apoptotic proteins ([@bib10]). Thus, the development of an effective strategy to target cancer stem cell pools together with conventional chemotherapies is essential to eradicate a tumour mass ([@bib4]). Recently, a CD133^+^ subpopulation of multipotent cells with extensive proliferative and self-renewal abilities was identified as cancer stem cells and was proven to contribute to the initiation and growth of HCC ([@bib12]). Here, we showed that CD133 expression level is correlated with JNK activity and predicts response to sorafenib in human HCC. In addition, pharmacologic inhibition of JNK has reduced tumour-initiating capacity of CD133^+^ cells, suggesting that JNK activation in CD133^+^ HCC cells enhances their tumourigenic capacity. Given that increased JNK activity contributes to proliferative advantage ([@bib16]; [@bib9]), the majority of HCC cells differentiated from CD133^+^ HCC cells with increased JNK activity would inherit the phenotype and exhibit the enhanced JNK activation.

Surrogate biomarkers that predict the biological and clinical efficacy of sorafenib will help tailor treatment on an individual patient basis. The predictive value of Raf/MEK/ERK signalling activity for the efficacy of sorafenib in HCC remains uncertain ([@bib1]; [@bib2]; [@bib13]). To date, a robust predictive biomarker has not been developed. In this study, we found a strong correlation between elevated JNK activity and poor therapeutic response to sorafenib. Evaluation of JNK activity in HCC can be useful to differentiate between responders and non-responders before starting sorafenib treatment and help to select patients who are likely to benefit from the treatment. In addition to ERK-mediated HCC cell growth, sorafenib also targets tumour angiogenesis by inhibiting the receptor tyrosine kinases of VEGF receptor (VEGFR)-1, VEGFR-2, VEGFR-3 and platelet-derived growth factor receptor *α* and *β* and stem cell factor receptor (KIT) ([@bib21], [@bib20]). Thus, the extent of angiogenesis might be a biomarker that can predict clinical efficacy of sorafenib. However, there was no significant relationship between tumour angiogenesis as assessed by CD31 staining and the therapeutic response to sorafenib (data not shown). c-Jun N-terminal kinase activity should be an independent predictive biomarker for sorafenib efficacy although this study is based on limited data of 39 patients from a single institution and further studies are needed to validate its value. Furthermore, we demonstrated that elevated JNK activity in HCC was associated with poor prognosis of patients treated with sorafenib. The ERK and JNK signalling pathways would activate mutually exclusive downstream molecules to contribute to HCC development. Consistently, JNK activation partially rescued sorafenib-induced cell toxicity, but was not sufficient to confer resistance to sorafenib ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). These data suggest the possibility of using a JNK inhibitor as a second-line treatment of advanced HCC ([Figure 6](#fig6){ref-type="fig"}). In this study, we found that in human HCC, the activation of JNK and high expression level of CD133 are associated with resistance to sorafenib. CD133 expression level is linked to JNK activity whose inhibition significantly reduces tumourigenesis of human CD133^+^ HCC cells after xenotransplantation. Our results demonstrate the importance of JNK in human HCC, and the potential application of JNK targeting for HCC therapy.
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![Association between JNK activation and poor therapeutic response to sorafenib in HCC. (**A**) Expression of phospho-c-Jun in HCC of patients with poor response (PD, *n*=18) and favourable response to sorafenib (PR, SD, *n*=17). Paraffin-embedded liver sections were immunostained with anti-phospho-c-Jun antibody. (**B**) Frequency of phospho-c-Jun-positive cells in HCCs. Data are the mean values±s.e. (**C**) Expression of phospho-JNK in HCC of patients with poor response (PD) and favourable response to sorafenib (PR, SD). Paraffin-embedded liver sections were immunostained with anti-phospho-JNK antibody.](bjc2012145f1){#fig1}

![Association between JNK activation, decreased time to progression and OS in patients treated with sorafenib. The Kaplan--Meier method was used to determine progression-free survival (**A**) and cumulative survival (**B**). The log-rank test was used to compare progression-free survival and cumulative survival between patients grouped according to phospho-c-Jun expression levels.](bjc2012145f2){#fig2}

![Relationship between CD133, p-c-Jun, p-JNK and p-ERK expression levels in HCCs. (**A**) Lysates of human HCCs were gel separated and analysed by immunoblotting with antibodies to the indicated proteins. (**B**) There was a significant positive correlation between CD133 and p-JNK/c-Jun expressions. There was no significant correlation between CD133 and p-ERK expressions.](bjc2012145f3){#fig3}

![Correlation between CD133 expression and response to sorafenib. (**A**) Expression of CD133 in HCCs. Representative immunostaining of cases who exhibited PR (left) and PD (right). Paraffin-embedded liver sections were immunostained with anti-CD133 antibody. (**B**) Among 17 non-responders (PD), 8 cases exhibited CD133-positive cells. Among 18 responders (PR or SD), only three cases exhibited CD133-positive cells.](bjc2012145f4){#fig4}

![Effect of a JNK inhibitor on tumourigenic potential of CD133^+^ HCC cells. (**A**) HepG2 cells positive or negative for CD133 were inoculated subcutaneously at 8 × 10^4^ cells per body into nude mice (*n*=8). From 1 week after subcutaneous inoculation, TAT control peptide and D-JNKi, a specific JNK inhibitor, were administered at 25 nmol per mouse once a week and the mice were autopsied 4 weeks later. Representative nude mice with subcutaneous tumours derived from CD133^+^ (left) and CD133^−^ (right) HepG2 cells. (**B**) Tumourigenicity of CD133^+^ or CD133^−^ HepG2 cells treated with D-JNKi or control Tat protein. (**C**) HuH7 cells positive for CD133 were inoculated subcutaneously at 1 × 10^6^ cells per body into nude mice (*n*=6). From 1 week after subcutaneous inoculation, TAT control peptide and D-JNKi were administered at 25 nmol per mouse once a week and the mice were autopsied 4 weeks later. Representative nude mice with subcutaneous tumours were shown. (**D**) Tumourigenicity of CD133^+^ HuH7 cells treated with D-JNKi or control Tat protein. (**E**) Expression of phospho-c-Jun in xenografted tumours treated with D-JNKi or control protein. (**F**) Expression of phospho-JNK in xenografted tumours treated with D-JNKi or control protein.](bjc2012145f5){#fig5}

![Association between sorafenib and the MAPK cascade. Sorafenib inhibits the Raf/ERK signalling pathway but not the JNK signalling pathway. The therapeutic efficacy of sorafenib would be limited when JNK is activated in HCCs. Treatment with sorafenib in combination with a JNK inhibitor might open promising therapeutic perspectives.](bjc2012145f6){#fig6}

###### Comparison of patient characteristics according to the anticancer effect

  **Variable**                           **Responder (PR+SD) (*****n*****=18)**   **Non-responder (PD) (*****n*****=17)**   ***P*****-value**
  -------------------------------------- ---------------------------------------- ----------------------------------------- -------------------
  Age -- years                           70.5 (54--78)                            74 (35--80)                               0.95
                                                                                                                             
  *Sex -- no. (%)*                                                                                                          1
   Male                                  13 (72)                                  12 (71)                                    
   Female                                5 (28)                                   5 (29)                                     
                                                                                                                             
  *Cause of disease -- no. (%)*                                                                                             0.82
   Hepatitis B                           3 (17)                                   4 (24)                                     
   Hepatitis C                           9 (50)                                   9 (53)                                     
   Non-B, non-C                          6 (33)                                   4 (24)                                     
                                                                                                                             
  *ECOG performance status -- no. (%)*                                                                                      0.49
   0                                     18 (100)                                 16 (94)                                    
   1                                     0 (0)                                    1 (6)                                      
                                                                                                                             
  *BCLC stage -- no. (%)*                                                                                                   0.51
   B (intermediate)                      11 (61)                                  8 (47)                                     
   C (advanced)                          7 (39)                                   9 (53)                                     
                                                                                                                             
  *Tumour grade -- no. (%)*                                                                                                 0.62
   Well                                  2 (11)                                   0 (0)                                      
   Moderate                              11 (61)                                  12 (71)                                    
   Poor                                  5 (28)                                   5 (29)                                     
                                                                                                                             
  AFP (ng ml^−1^) -- median (range)      276 (2--22 619)                          89 (3--228 540)                           0.56
                                                                                                                             
  DCP (mAU ml^−1^) -- median (range)     641 (5--26 624)                          481.5 (9--61 180)                         0.93
                                                                                                                             
  *Previous therapy (last) -- no. (%)*                                                                                      0.09
   OP                                    1 (6)                                    5 (29)                                     
   RFA                                   1 (6)                                    2 (12)                                     
   TACE                                  11 (61)                                  10 (59)                                    
   HAIC                                  3 (17)                                   0 (0)                                      
   None                                  2 (11)                                   0 (0)                                      

Abbreviations: ECOG=Eastern Cooperative Oncology Group; BCLC=Barcelona Clinic Liver Cancer; AFP=*α*-fetoprotein; DCP=des-*γ*-carboxyprothrombin; OP=operation; RFA=radiofrequency ablation; TACE=transcatheter arterial chemoembolization; HAIC=hepatic arterial chemotherapy using implanted port system; PR=partial response; SD=stable disease; PD=progressive disease.
